medric medric
[닫기]
잠시만 기다려 주세요. 로딩중입니다.

Influence of hepatic steatosis on the outcomes of patients with chronic hepatitis B treated with entecavir and tenofovir

Clinical and Molecular Hepatology 2019년 25권 3호 p.283 ~ 293
 ( Kim David Soo-Ik ) - Yonsei University College of Medicine Department of Internal Medicine

 ( Jeon Mi-Young ) - Yonsei University College of Medicine Department of Internal Medicine
 ( Lee Hye-Won ) - Yonsei University College of Medicine Department of Internal Medicine
김범경 ( Kim Beom-Kyung ) - Yonsei University College of Medicine Department of Internal Medicine
박준용 ( Park Jun-Yong ) - Yonsei University College of Medicine Department of Internal Medicine
김도영 ( Kim Do-Young ) - Yonsei University College of Medicine Department of Internal Medicine
 ( Ahn Sang-Hoon ) - Yonsei University College of Medicine Department of Internal Medicine
 ( Han Kwang-Hyub ) - Yonsei University College of Medicine Department of Internal Medicine
 ( Kim Seung-Up ) - Yonsei University College of Medicine Department of Internal Medicine

Abstract


Background/Aims: The influence of hepatic steatosis (HS) on chronic hepatitis B (CHB) is unclear. We evaluated the influence of the degree of HS, assessed using the controlled attenuation parameter (CAP) of transient elastography (TE), on treatment outcomes in CHB patients initiated on antiviral therapy.

Methods: A total of 334 patients who were initiated on entecavir or tenofovir between 2007 and 2016 with available TE results were recruited.

Results: Of the total study population, 146 (43.7%) patients had HS (CAP > 238 dB/m). Three-hundred-three patients (90.7%) achieved complete virological response (CVR) (hepatitis B virus DNA<12 IU/L), and 25 patients (7.5%) developed hepatocellular carcinoma (HCC). Among hepatitis B e antigen (HBeAg)-positive patients (n=172, 51.5%), 37 (21.5%) experienced HBeAg loss. On univariate analysis, CAP value was not associated with the probability of HCC development (P=0.380). However, lower CAP value was independently associated with higher probability of HBeAg loss among HBeAg-positive patients (hazard ratio [HR]=0.991, P=0.026) and with CVR achievement in the entire study population (HR=0.996, P=0.004). The cumulative incidence of HBeAg loss among HBeAg-positive patients was significantly higher in patients without HS than in those with HS (log-rank, P=0.022).

Conclusions: CAP values were not correlated with HCC development in patients initiated on entecavir and tenofovir. However, CAP values were negatively correlated with the probability of HBeAg loss among HBeAg-positive patients and with CVR achievement.

키워드

Fatty liver; Hepatitis B, Chronic; Antiviral agent
원문 및 링크아웃 정보
 
등재저널 정보